Pooled Phase II data for PT003 appear to suggest the therapeutic has the potential to be at least comparable to other combinations of long-acting muscarinic antagonist (LAMA) and long-acting adrenergic receptor beta 2 agonists (LABAs) in terms of efficacy in chronic obstructive pulmonary disease (COPD). However, the final verdict will have to wait, as variations in endpoints, comparators and trial lengths from available data make comparing the different combinations difficult. AstraZeneca plc (LSE:AZN; NYSE:AZN) obtained PT003 from its acquisition of Pearl Therapeutics Inc. in June. (A) Data are statistically significant unless